
|Articles|May 28, 2015 (Updated: October 7, 2020)
- Genitourinary (Issue 2)
- Issue 2
Use of ARN-509 in Prostate Cancer
Author(s)Charles J. Ryan, MD
Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.
Articles in this issue
almost 11 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCalmost 11 years ago
Multiparametric MRI Effective, Affordable for Prostate Cancer Detectionalmost 11 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisalmost 11 years ago
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPCalmost 11 years ago
PSA Screening Drops 50% Following USPSTF Recommendationalmost 11 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Canceralmost 11 years ago
Trends in PSA Utilization in Primary Care Physiciansalmost 11 years ago
AR-V7 as a Biomarker in CRPC






























